arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Aldeyra Therapeutics, Inc.

ALDX
$1.23 ▼ -0.11 (-8.58%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Aldeyra Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $74.2M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -12.2% ↘
FCF / Share $-0.08 ↗
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 24, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-5.45M
↑ +44.2% —
FCF / Share Free cash flow per share
$-0.08
↑ +10.2% —
Long-Term Debt Long-term obligations
$15.30M
— 0.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
12
Financial Health ↑
42
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 14 years · 65 quarters